Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised multicentre open adaptive multi-arm multi-stage trial

Catalyst investigators, Pamela Kearns(National Institute for Health and Care Research), Tonny Veenith(New Cross Hospital), Nicholas Morley(Royal Hallamshire Hospital), Charlotte Gaskell(Cancer Research UK Clinical Trials Unit), Joanna Porter, David Thickett(Centre for Inflammation Research), Julian Bion(Clinical Trial Investigators), Matthew Rowland(University of Oxford), Dhruv Parekh(University Hospitals Birmingham NHS Foundation Trust), Philip N. Newsome(King's College London), James Scriven(University Hospitals Birmingham NHS Foundation Trust), Rowena Sharpe(Cancer Research UK Clinical Trials Unit), Duncan Richards(University of Oxford), Matt P. Wise(University Hospital of Wales), Daniel Slade(Temple University), Anna Rowe(University Hospitals Birmingham NHS Foundation Trust), Ling‐Pei Ho(University of Oxford), Helen McShane(University of Oxford), Madhu Balasubramaniam(Royal Bolton Hospital), Simon Gates(Oxford Brookes University), G Cooke, Benjamin A. Fisher(Birmingham City University), Zoë Gabriel(Sheffield Teaching Hospitals NHS Foundation Trust), Tony Whitehouse(Queen Elizabeth Hospital Birmingham)

Unknown

October 12, 2021

Cited by 0

|Intensive Care Medicine|2007|4.9k

|Cochrane Database of Systematic Reviews|2012|3.9k

|Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)|2008|3.9k

|New England Journal of Medicine|2013|2.8k

|Cochrane Database of Systematic Reviews|2013|1.2k

Related Papers